OCGN vs SRPT
OCGN: A gene therapy company developing novel modifier gene therapies to treat inherited retinal diseases, including retinitis pigmentosa, Stargardt disease, and geographic atrophy. SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
Side-by-side fundamentals
| Metric | OCGN | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $1.29 | $15.82 | |
| Market cap as of 2026-07-23 | $440M | $1.7B | |
| P/E as of 2026-07-23 | n/a | 26.31 | |
| PEG as of 2026-07-23 | -0.23 | -23.53 | SRPT lower |
| Net margin as of 2026-07-23 | -1158.6% | +3.0% | SRPT higher |
| Gross margin as of 2026-07-23 | n/a | +70.5% | |
| Operating margin as of 2026-07-23 | -1057.5% | -1.1% | SRPT higher |
| ROE as of 2026-07-23 | -1306.7% | +4.9% | SRPT higher |
| ROA as of 2026-07-23 | -96.3% | +1.9% | SRPT higher |
| Debt / equity as of 2026-07-23 | 5.03 | 0.56 | SRPT lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.0% | -2.2% | OCGN higher |
| Revenue CAGR (3y) SEC XBRL | +21.0% | +33.1% | SRPT higher |
| Beta as of 2026-07-23 | 2.17 | 0.19 | |
| 1-year return as of 2026-07-22 close | +25.2% | +16.2% | OCGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.